AUTHOR=Weng Hong , Zeng Xian-Tao , Wang Xing-Huan , Liu Tong-Zu , He Da-Lin 

TITLE=Genetic Association between Matrix Metalloproteinases Gene Polymorphisms and Risk of Prostate Cancer: A Meta-Analysis

JOURNAL=Frontiers in Physiology

VOLUME=8

YEAR=2017

URL=https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2017.00975

DOI=10.3389/fphys.2017.00975

ISSN=1664-042X

ABSTRACT=<p><bold>Background and Objective:</bold> Studies suggests that <italic>matrix metalloproteinase</italic> (<italic>MMP</italic>)<italic>-2</italic>-1306 C/T and <italic>MMP-1</italic>-1607 1G/2G polymorphisms affect the risk of prostate cancer. However, the conclusions remain controversial and no pooled evidence of this topic has been published. Therefore, we aimed to perform a meta-analysis to shed some light on the controversial conclusion pertaining to the associations of <italic>MMP-2</italic>-1306 C/T and <italic>MMP-1</italic>-1607 1G/2G polymorphisms with prostate cancer susceptibility.</p><p><bold>Methods:</bold> A thorough literature search was performed up to August, 2016 with the PubMed, EMBASE, CBM, CNKI, and Wanfang databases. Odds ratios (ORs) and corresponding 95% confidence intervals (95% CIs) were calculated to address the correlations between these polymorphisms and risk of prostate cancer.</p><p><bold>Results:</bold> The meta-analysis included six studies (1,921 patients and 1,988 controls) on <italic>MMP-2</italic>-1306 C/T polymorphism and three studies on <italic>MMP-1</italic>-1607 1G/2G polymorphism (438 patients and 394 controls), respectively. The overall results of meta-analysis showed that an elevated risk of the disease was implicated in <italic>MMP-2</italic>-1306 C/T polymorphism under two genetic models (CT vs. CC: OR = 1.78, 95% CI = 1.33–2.38; TT+CT vs. CC: OR = 1.62, 95% CI = 1.24–2.12) and no significant association was observed between <italic>MMP-1</italic>-1607 1G/2G polymorphism and the risk of prostate cancer. The subgroup analysis results of <italic>MMP-2</italic>-1306 C/T polymorphism were similar to the overall results. However, decreased risk of prostate cancer was observed in the Caucasians for <italic>MMP-1</italic>-1607 1G/2G polymorphism.</p><p><bold>Conclusions:</bold> Current meta-analysis indicates that <italic>MMP-2</italic>-1306 C/T polymorphism is associated with elevated risk of prostate cancer, but <italic>MMP-1</italic>-1607 1G/2G polymorphism may inhibit the occurrence of prostate cancer in Caucasians. Further studies are warranted to verify the conclusions.</p>